A. Malmberg

1.2k total citations
13 papers, 832 citations indexed

About

A. Malmberg is a scholar working on Pulmonary and Respiratory Medicine, Political Science and International Relations and Oncology. According to data from OpenAlex, A. Malmberg has authored 13 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Political Science and International Relations and 3 papers in Oncology. Recurrent topics in A. Malmberg's work include Prostate Cancer Treatment and Research (4 papers), Regional Development and Policy (3 papers) and Hormonal and reproductive studies (2 papers). A. Malmberg is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Regional Development and Policy (3 papers) and Hormonal and reproductive studies (2 papers). A. Malmberg collaborates with scholars based in United Kingdom, Sweden and Denmark. A. Malmberg's co-authors include Peter Maskell, Dominic Power, Sue Simkin, Louis Appleby, Keith Hawton, Stephen Platt, Ash Amin, Örjan Sölvell, Ulf Holm and Zsolt Bosnyák and has published in prestigious journals such as Annals of Oncology, Journal of Affective Disorders and Environment and Planning A Economy and Space.

In The Last Decade

A. Malmberg

13 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Malmberg United Kingdom 5 267 258 227 175 163 13 832
Claudia Schmiedeberg Germany 12 132 0.5× 241 0.9× 179 0.8× 55 0.3× 177 1.1× 29 753
Paul D. Reynolds United States 13 89 0.3× 113 0.4× 42 0.2× 74 0.4× 128 0.8× 35 558
Richard Freeman United Kingdom 15 51 0.2× 80 0.3× 49 0.2× 263 1.5× 220 1.3× 30 821
Jeffrey B. Wenger United States 13 32 0.1× 159 0.6× 64 0.3× 117 0.7× 156 1.0× 69 573
John Shutt United Kingdom 12 47 0.2× 119 0.5× 38 0.2× 170 1.0× 129 0.8× 32 482
Sophie Yates Australia 16 80 0.3× 31 0.1× 80 0.4× 162 0.9× 203 1.2× 39 681
Hillel Schmid Israel 17 82 0.3× 38 0.1× 104 0.5× 56 0.3× 584 3.6× 77 944
Dennis R. Maki Canada 15 62 0.2× 261 1.0× 61 0.3× 57 0.3× 86 0.5× 63 652
Martin Williams United Kingdom 14 36 0.1× 114 0.4× 65 0.3× 133 0.8× 141 0.9× 24 596
James Chowhan Canada 13 54 0.2× 74 0.3× 104 0.5× 13 0.1× 148 0.9× 38 642

Countries citing papers authored by A. Malmberg

Since Specialization
Citations

This map shows the geographic impact of A. Malmberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Malmberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Malmberg more than expected).

Fields of papers citing papers by A. Malmberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Malmberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Malmberg. The network helps show where A. Malmberg may publish in the future.

Co-authorship network of co-authors of A. Malmberg

This figure shows the co-authorship network connecting the top 25 collaborators of A. Malmberg. A scholar is included among the top collaborators of A. Malmberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Malmberg. A. Malmberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Vergote, I., Nicole Concin, Mansoor Raza Mirza, et al.. (2019). Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8). Annals of Oncology. 30. v433–v434. 2 indexed citations
3.
Xie, Liping, et al.. (2016). 848 Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China. European Urology Supplements. 15(3). e848–e848. 1 indexed citations
4.
5.
Boccon-Gibod, L, et al.. (2015). 565 Factors predicting the off-treatment duration during intermittent androgen deprivation (IAD) therapy with degarelix in prostate cancer. European Urology Supplements. 14(2). e565–e565a. 1 indexed citations
6.
Holm‐Larsen, Tove, A. Malmberg, Egbert van der Meulen, & Jens Peter Nørgaard. (2015). 274 Is the reduction to less than two nocturnal voids a relevant clinical treatment goal in nocturia patients?. European Urology Supplements. 14(2). e274–e274a. 1 indexed citations
7.
8.
Power, Dominic & A. Malmberg. (2008). The contribution of universities to innovation and economic development: in what sense a regional problem?. Cambridge Journal of Regions Economy and Society. 1(2). 233–245. 109 indexed citations
9.
Maskell, Peter & A. Malmberg. (2007). Myopia, knowledge development and cluster evolution. Journal of Economic Geography. 7(5). 603–618. 328 indexed citations
10.
Holm, Ulf, A. Malmberg, & Örjan Sölvell. (2003). Subsidiary impact on host-country economies--the case of foreign-owned subsidiaries attracting investment into sweden. Journal of Economic Geography. 3(4). 389–408. 35 indexed citations
11.
Montán, S., Katarina Svanberg, Stefan Andersson‐Engels, et al.. (1999). NIR Raman spectroscopy for cardiovascular tissue characterisation. Biomedical optics. BTuC5–BTuC5. 2 indexed citations
12.
Hawton, Keith, et al.. (1998). Product review. Journal of Affective Disorders. 50(2-3). 269–276. 283 indexed citations
13.
Amin, Ash & A. Malmberg. (1992). Competing Structural and Institutional Influences on the Geography of Production in Europe. Environment and Planning A Economy and Space. 24(3). 401–416. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Schmiedeberg Breakdown of academic impact, for papers by Paul D. Reynolds Breakdown of academic impact, for papers by Richard Freeman Breakdown of academic impact, for papers by Jeffrey B. Wenger Breakdown of academic impact, for papers by John Shutt Breakdown of academic impact, for papers by Sophie Yates Breakdown of academic impact, for papers by Hillel Schmid Breakdown of academic impact, for papers by Dennis R. Maki Breakdown of academic impact, for papers by Martin Williams Breakdown of academic impact, for papers by James Chowhan
Rankless by CCL
2026